Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person UniProt:Q9Y5C1 ANGPTL3

Class:Id	ReferenceGeneProduct:50000
_chainChangeLog	signal peptide:1-16 added on Fri February 6 2015;chain:17-460 added on Fri February 6 2015;chain:17-224 added on Fri May 6 2016;chain:17-221 added on Fri May 6 2016
_displayName	UniProt:Q9Y5C1 ANGPTL3
_timestamp	2024-11-03 20:17:51
chain	signal peptide:1-16 chain:17-460 chain:17-224 chain:17-221
checksum	6279465FEEB91F56
comment	FUNCTION Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism (PubMed:11788823, PubMed:12909640, PubMed:23661675, PubMed:25495645). Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake (By similarity). Has a stimulatory effect on plasma triglycerides (TG), which is achieved by suppressing plasma TG clearance via inhibition of LPL activity. The inhibition of LPL activity appears to be an indirect mechanism involving recruitment of proprotein convertases PCSK6 and FURIN to LPL leading to cleavage and dissociation of LPL from the cell surface; the function does not require ANGPTL3 proteolytic cleavage but seems to be mediated by the N-terminal domain, and is not inhibited by GPIHBP1 (PubMed:12097324, PubMed:19318355, PubMed:20581395). Can inhibit endothelial lipase, causing increased plasma levels of high density lipoprotein (HDL) cholesterol and phospholipids (PubMed:17110602, PubMed:19028676). Can bind to adipocytes to activate lipolysis, releasing free fatty acids and glycerol (PubMed:12565906). Suppresses LPL specifically in oxidative tissues which is required to route very low density lipoprotein (VLDL)-TG to white adipose tissue (WAT) for storage in response to food; the function may involve cooperation with circulating, liver-derived ANGPTL8 and ANGPTL4 expression in WAT (By similarity). Contributes to lower plasma levels of low density lipoprotein (LDL)-cholesterol by a mechanism that is independent of the canonical pathway implicating APOE and LDLR. May stimulate hypothalamic LPL activity (By similarity).FUNCTION In vitro inhibits LPL activity; not effective on GPIHBP1-stabilized LPL.FUNCTION Involved in angiogenesis. Binds to endothelial cells via integrin alpha-V/beta-3 (ITGAV:ITGB3), activates FAK, MAPK and Akt signaling pathways and induces cell adhesion and cell migration (PubMed:11877390). Secreted from podocytes, may modulate properties of glomerular endothelial cells involving integrin alpha-V/beta-3 and Akt signaling (PubMed:18535744). May increase the motility of podocytes. May induce actin filament rearrangements in podocytes implicating integrin alpha-V/beta-3 and Rac1 activation. Binds to hematopoietic stem cells (HSC) and is involved in the regulation of HSC activity probably implicating down-regulation of IKZF1/IKAROS (By similarity).SUBUNIT Interacts with ANGPTL8. Interacts with ITGB3 (By similarity).SUBCELLULAR LOCATION Colocalized with HSPG2 and activated ITGB3 on podocytes.TISSUE SPECIFICITY Expressed principally in liver. Weakly expressed in kidney. Binds to adipocytes. Increased expression and colocalization with activated ITGB3 in glomeruli of patients with nephrotic syndrome showing effaced podocyte foot processes (at protein level).INDUCTION Down-regulated by insulin.DOMAIN The fibrinogen C-terminal domain is sufficient to mediate endothelial cell adhesion.PTM O-glycosylated at Thr-226 by GALNT2; blocks processing and activation by proprotein convertases.PTM In part proteolytically cleaved by proprotein convertases; proposed to be involved in activation.DISEASE The disease is caused by variants affecting the gene represented in this entry.DISEASE May be involved in atherosclerosis. Plasma levels are closely associated with arterial wall thickness.DISEASE May be involved in nephrotic syndrome.MISCELLANEOUS Was suggested to inhibit LPL through a direct mechanism; however, the necessary concentration to achieve in vitro inhibition is at least 30-fold higher than ANGPTL3 plasma concentration.SEQUENCE CAUTION Contaminating sequence. Potential poly-A sequence.
description	recommendedName: Angiopoietin-related protein 3 alternativeName: Angiopoietin-5 shortName: ANG-5 alternativeName: Angiopoietin-like protein 3 component recommendedName: ANGPTL3(17-221) /component component recommendedName: ANGPTL3(17-224) /component
geneName	ANGPTL3 ANGPT5 UNQ153/PRO179
identifier	Q9Y5C1
isSequenceChanged	FALSE
keyword	3D-structure Angiogenesis Cell adhesion Cell projection Coiled coil Direct protein sequencing Disulfide bond Glycoprotein Heparin-binding Lipid metabolism Proteomics identification Reference proteome Secreted Signal
modified	[InstanceEdit:9836292] Weiser, Joel, 2023-05-25 [InstanceEdit:9852000] Weiser, Joel, 2023-11-03 [InstanceEdit:9926675] Weiser, Joel, 2024-11-03
name	ANGPTL3
referenceDatabase	[ReferenceDatabase:2] UniProt
referenceGene	[ReferenceDNASequence:8999316] ENSEMBL:ENSG00000132855 ANGPTL3 [Homo sapiens]
secondaryIdentifier	ANGL3_HUMAN A0JLS0 B1ALJ0 B2RCW1
sequenceLength	460
species	[Species:48887] Homo sapiens
(referenceEntity)	[EntityWithAccessionedSequence:6784858] ANGPTL3(?-460) [extracellular region] [Homo sapiens] [EntityWithAccessionedSequence:6784896] ANGPTL3(1-?) [extracellular region] [Homo sapiens] [EntityWithAccessionedSequence:6784898] ANGPTL3 [extracellular region] [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by UniProt:Q9Y5C1 ANGPTL3 (50000)